US Starts Section 301 Probe of Germany Over Pharmaceuticals

The Trump administration, through the U.S. Trade Representative (USTR), has launched a Section 301 investigation into Germany's pharmaceutical pricing policies. This action follows concerns that Germany, along with other nations, is not paying its fair share for pharmaceutical innovation, thereby burdening American patients and taxpayers who end up subsidizing global drug research and development.

U.S. officials have been actively engaging European governments, including Germany, to increase their spending on medicines. This effort, described as a "charm offensive," highlights that American patients pay significantly more for drugs—around three times more than consumers in Germany for new medications. The U.S. aims for Germany to increase its drug spending, especially as Germany is currently overhauling its healthcare laws with intentions to cut federal spending on medicines.

This investigation has received support from members of Congress, including Congressman Vern Buchanan, who chairs the Health Subcommittee of the House Ways and Means Committee. Lawmakers urged USTR to move forward with the probe, citing Germany's continued plans to reduce pharmaceutical spending despite warnings. The Section 301 investigation provides a mechanism for the U.S. to address what it perceives as unfair trade practices and potentially impose tariffs, similar to threats made by the Trump administration in the past, or negotiate agreements like the one secured with the UK that saw increased drug spending.

Pharmaceutical companies, such as Eli Lilly and Boehringer Ingelheim, have already responded to Germany's cost-cutting plans by reducing billions of euros in planned investments in the country. The U.S. also plans to implement a "most-favored nation" drug pricing policy, effective January, which would link U.S. drug prices to the lowest prices in a basket of wealthy countries, including Germany. This policy has led to threats from pharmaceutical companies not to launch products in these basket countries if prices are too low, preferring higher prices in the U.S.